Welcome to LookChem.com Sign In|Join Free

CAS

  • or

138491-18-6

Post Buying Request

138491-18-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

138491-18-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 138491-18-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,4,9 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 138491-18:
(8*1)+(7*3)+(6*8)+(5*4)+(4*9)+(3*1)+(2*1)+(1*8)=146
146 % 10 = 6
So 138491-18-6 is a valid CAS Registry Number.

138491-18-6Downstream Products

138491-18-6Relevant articles and documents

Synthesis of halogenated trimetoquinol derivatives and evaluation of their β-agonist and thromboxane A2 (TXA2) antagonist activities

Markovich,Tantishaiyakul,Hamada,Miller,Romstedt,Shams,Shin,Fraundorfer,Doyle,Feller

, p. 466 - 479 (2007/10/02)

The 5,8-difluoro (4), 5-iodo (5), 8-iodo (6), and 5-trifluoromethyl (7) derivatives of trimetoquinol (TMQ, 1) have been synthesized and evaluated for their ability to stimulate β1 (guinea pig atria) and β2 (guinea pig trachea) adrenoceptors as well as for their inhibitory activity against U46619 [a thromboxane A2 (TXA2) mimetic]-mediated contraction of rat thoracic aorta and human platelet aggregation. Both 5 and 6 were considerably less active than TMQ on both β-adrenergic systems and gave a rank order of stimulatory potency of 1 >> 6 ≥ 5. Similarly, iodine substitution at either position also caused a reduction in TXA2 antagonist activity with a rank order potency of 1 > 6 >> 5. Compared to 1, however, 5-iodo-TMQ (5) showed a marked selectivity for blockade of U46619 responses in rat aorta over human platelets. On β-systems, 4 had reduced potency compared to TMQ and was similarly nonselective. Introduction of a trifluoromethyl group at the 5- position of TMQ completely abolished both β1- and β2-adrenergic agonist activities while imparting weak antagonist activity on β1 receptors. On TXA2 systems, both 4 and 7 possessed significantly decreased inhibitory activity compared to TMQ. The synthetic approaches to the synthesis of 8- (trifluoromethyl)-TMQ (8) are also described. The enantiomers of the 8-fluoro derivative (3) of TMQ were separated on a preparative Chiralcel OD column and evaluated on β-adrenergic systems and TXA2 systems. On β-adrenergic systems, (S)-(+)-8-fluoro-TMQ was at least 10-fold more potent than (R)-(-)- 8-fluoro-TMQ. Conversely, (R)-(-)-8-fluoro-TMQ was approximately 14-fold more potent as an antagonist of TXA2-mediated aggregation in human platelets than (S)-(+)-8-fluoro-TMQ. In contrast to platelets, (S)-(+)-8-fluoro-TMQ was an agonist in rat aorta whereas (R)-(-)-8-fluoro-TMQ was an antagonist.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 138491-18-6